Soni Manmeet Singh reported option exercise involving 100,000 shares of Summit Therapeutics Inc. at $1.37 for $137k on Nov 16, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
COO and CFO
COO and CFO
Filed Nov 16, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$137,000Shares × reported price
Shares traded
100,000Common Stock
Price per share
$1.37Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
3,224,375Direct
Trade date
Nov 16, 2026Option exercise
Filed
Nov 16, 2026, 7:49 PM ET1-day reporting delay
Accession
0001569769-26-000008Code M · Transaction 402276
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 16, 2026Option exercise100,000$0.00$0Trade 402277
2 transaction rows in this filing. Joint filers share the same rows.

SMMT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SMMT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −2.9%1w ago +18%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: On November 16, 2026, the Reporting Person exercised an option to purchase 100,000 shares of the Issuer's common stock at an exercise price of $1.37 per share. F2: Holdings include shares previously acquired through exempt transactions pursuant to the Issuer's employee stock purchase plan. F3: The option was granted on December 23, 2019. The shares underlying the option vested in four equal annual installments, with the first such installment beginning on December 23, 2020.